Prospects for use of Vericiguat in HFrEF: Implications of VICTORIA Trial Results. Advisory Board Summary

被引：1

作者：

Belenkov, Yu. N. ^{[1
]}

Arutyunov, G. P. ^{[2
]}

Mareev, V. Yu ^{[3
]}

Koziolova, N. A. ^{[4
]}

Sitnikova, M. Yu ^{[5
]}

Ageev, F. T. ^{[6
]}

Gilyarevsky, S. R. ^{[7
]}

Chesnikova, A., I ^{[8
]}

Yakushin, S. S. ^{[9
]}

Perepech, N. B. ^{[10
]}

Mareev, Yu., V ^{[3
,11
]}

机构：

[1] Sechenov First Moscow State Med Univ, Moscow, Russia

[2] Pirogov Russian Natl Res Med Univ, Moscow, Russia

[3] Lomonosov Moscow State Univ, Med Res & Educ Ctr, Moscow, Russia

[4] Vagner Perm State Med Univ, Perm, Russia

[5] Almazov Natl Med Res Ctr, St Petersburg, Russia

[6] Chazov Natl Med Res Ctr Cardiol, Moscow, Russia

[7] Russian Med Acad Continuous Profess Educ, Moscow, Russia

[8] Rostov State Med Univ, Rostov Na Donu, Russia

[9] Pavlov Ryazan State Med Univ, Ryazan, Russia

[10] St Petersburg State Univ, St Petersburg, Russia

[11] Natl Med Res Ctr Therapy & Prevent Med, Moscow, Russia

来源：

KARDIOLOGIYA | 2023年 / 63卷 / 04期

关键词：

Chronic heart failure; heart failure with reduced ejection fraction; vericiguat; prognosis; HEART-FAILURE;

D O I：

10.18087/cardio.2023.4.n2403

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In September 2021, an online meeting of the Council of Experts was held. The proposed focus of discussion was publishing the results of an international prospective, randomized, double-blind, placebo-controlled study VICTORIA. The objective of the VICTORIA study was evaluation of the efficacy and safety of supplementing a standard therapy with vericiguat at a target dose of 10 mg twice a day as compared to placebo for prevention of cardiovascular death and hospitalization for heart failure (HF) in patients with clinical manifestations of chronic HF and left ventricular ejection fraction <45% who have recently had an episode of decompensated HF. The aim of the meeting was interpretation of the VICTORIA study results on efficacy and safety of vericiguat for a potential use in a Russian population of patients after a recent episode of decompensated chronic HF with reduced ejection fraction.

引用

页码：3 / 10

页数：7

共 17 条

[1] Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Senni, M.
Alemayehu, W.
Sim, D.
Edelmann, F.
Butler, J.
Ezekowitz, J. A.
Hernandez, A. F.
Lam, C. S. P.
O'Connor, C. M.
Pieske, B.
Ponikowski, P.
Roessig, L.
Voors, A. A.
McMullan, C.
Armstrong, P. W.
EUROPEAN HEART JOURNAL, 2021, 42 : 788 - 788
[2] Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
Voors, Adriaan A.
Mulder, Hillary
Reyes, Eugene
Cowie, Martin R.
Lassus, Johan
Hernandez, Adrian F.
Ezekowitz, Justin A.
Butler, Javed
O'Connor, Christopher M.
Koglin, Joerg
Lam, Carolyn S. P.
Pieske, Burkert
Roessig, Lothar
Ponikowski, Piotr
Anstrom, Kevin J.
Armstrong, Paul W.
EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (08) : 1313 - 1321
[3] Diuretic use and outcomes in patients with HFrEF: Insights from the VICTORIA trial
Ezekowitz, J. A.
Alemayehu, W.
Edelmann, F.
Ponikowski, P.
Lam, C. S. P.
O'connor, C. M.
Butler, J.
Homering, M.
Corda, S.
Mcmullan, C. J.
Westerhout, C. M.
Voors, A. A.
Mentz, R. J.
Armstrong, P.
EUROPEAN HEART JOURNAL, 2023, 44
[4] Cost Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: Results From the VICTORIA Trial
Chew, Derek S.
Cowper, Patricia A.
Bigelow, Robert
Li, Yanhong
Anstrom, Kevin
Davidson-Ray, Linda D.
Hernandez, Adrian F.
O'Connor, Christopher M.
Armstrong, Paul
Mark, Daniel B.
CIRCULATION, 2021, 144 (25) : E586 - E586
[5] VENUS - Very early nimodipine use in stroke: Preliminary trial results.
Horn, J
Haan, R
Vermeulen, M
Limburg, M
STROKE, 1999, 30 (01) : 243 - 243
[6] COMMUNITY ADVISORY BOARD INPUT CAN MAKE LAY SUMMARIES OF CLINICAL TRIAL RESULTS MORE UNDERSTANDABLE
Welling, J.
Roennow, A.
Sauve, M.
Brown, E.
Galetti, I.
Gonzalez, A.
Guiraud, A. P. Portales
Kennedy, A.
Leite, C.
Riggs, R. J.
Zheng, A.
Popovic, M. Perkovic
Gilbert, A.
Moros, L.
Sroka-Saidi, K.
Schindler, T.
Finnern, H.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1286 - 1287
[7] WHAT ARE NEW OPPORTUNITIES FOR CLINICAL PRACTICE THE VERIFY STUDY OPENS AND WHICH VALUES FOR NATIVE DIABETES PATIENTS? JOINT CONCLUSION ON THE ADVISORY BOARD RESULTS. NOVEMBER 6, 2019
Shestakova, Marina, V
Antsiferov, Michail B.
Ametov, Alexander S.
Galstyan, Gagik R.
Demidova, Tatiana Y.
Zilov, Alexey, V
Markova, Tatyana N.
Petunina, Nina A.
Chernikova, Natalya A.
Shannkhalova, Minara S.
DIABETES MELLITUS, 2020, 23 (01): : 106 - 110
[8] PROSPECTS OF FINERENONE USE IN RUSSIAN POPULATION OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES. RESOLUTION OF MULTIDISCIPLINARY. ADVISORY BOARD
Shestakova, Marina V.
Dobronravov, Vladimir A.
Ametov, Alexander S.
Antsiferov, Mikhail B.
Batyushin, Mikhail M.
Bobkova, Irina N.
Galstyan, Gagik R.
Demidova, Tatyana Yu.
Klimontov, Vadim V.
Mkrtumyan, Ashot M.
Petunina, Nina A.
Prokopenko, Elena I.
Chebotareva, Natalia V.
Shamkhalova, Minara S.
DIABETES MELLITUS, 2023, 26 (05): : 492 - 499
[9] Safety implications of missed test results for hospitalised patients: the use of electronic discharge summary systems
Mitchell, Rob
Morrison, Stewart
BMJ QUALITY & SAFETY, 2011, 20 (08) : 733 - 733
[10] Medical oncologists' skill and understanding of epidemiology and statistical principles need to be strengthened to maximize their use of clinical trial results.
Hoffman, K. R.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 335S - 335S

← 1 2 →